Johnson & Johnson
NYSE:JNJDrug Manufacturers - General
-$4.59 today
- Market cap
- $656.47B
- Beta
- 0.26
- P/E (TTM)
- 26.7
- EPS (TTM)
- $8.60
- Dividend yield
- 2.28%
Volume 7.93M
Average 7.71M
JNJ EBITDA Margin
EBITDA as a percentage of revenue.
Johnson & JohnsonNYSE: JNJ
EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026
EBITDA Margin narrows to 25.1%
EBITDA Margin was 25.1% in Q3 FY2026, down 13.7 pp from a year earlier. On a trailing-twelve-month basis it was 31.0%, down 11.9 pp year over year. Over 3 fiscal years it widened by 10.3 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 16 analysts of 37.0% for the fiscal year ending Dec 2026, down from 43.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- 25.1%-10.4 pp QoQ
- Last fiscal yearDec 2025
- 43.6%+15.7 pp YoY
- LTMSep 2026
- 31.0%-11.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -13.7 pp | +9.0 pp | +22.6 pp |
| 1 year | +15.7 pp | -6.6 pp | -22.3 pp |
| 3 years | +10.3 pp | -5.8 pp | -16.2 pp |
| 5 years | -4.0 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 43.6%
- Year-over-year change
- +15.7pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 43.6% | +15.7pp |
| FY2024 | 2024-12-29 | 27.9% | +0.5pp |
| FY2023 | 2023-12-31 | 27.4% | -5.9pp |
| FY2022 | 2023-01-01 | 33.3% | -0.7pp |
| FY2021 | 2022-01-02 | 34.0% | — |
EBITDA Margin vs competitors
How JNJ compares with its peers on the latest reported figures
- JNJ's LTM Sep 2026 EBITDA Margin of 31.0% is the 6th highest of the 11 companies compared; the peer median is 32.2%.
- Its year-over-year change of -11.9 pp is the 9th highest of 11, against a peer median of -0.1 pp.
- Over three fiscal years its change of +10.3 pp compares with a peer median of +1.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 46.2% | +0.7 pp | -0.2 pp | |
| LTM Jun 2026 | 40.0% | -1.1 pp | +8.2 pp | |
| LTM Sep 2026 | 36.6% | +15.1 pp | -12.8 pp | |
| LTM Sep 2026 | 34.4% | +3.4 pp | +13.3 pp | |
| LTM Jun 2026 | 34.2% | +2.6 pp | -10.0 pp | |
| LTM Sep 2026 | 31.0% | -11.9 pp | +10.3 pp | |
| LTM Jun 2026 | 30.2% | +0.6 pp | -6.6 pp | |
| LTM Jun 2026 | 26.5% | -0.7 pp | +2.5 pp | |
| LTM Jun 2026 | 21.2% | -10.4 pp | -13.7 pp | |
| LTM Jun 2026 | 21.0% | -18.3 pp | +7.6 pp | |
| LTM Jun 2026 | 4.4% | -33.6 pp | +13.7 pp | |
| Peer median (excluding JNJ) | 32.2% | -0.1 pp | +1.1 pp | |
Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 78.74B | 79.99B | 85.16B | 88.82B | 94.19B |
| Cost of Revenue | 23.4B | 24.6B | 26.55B | 27.47B | 30.26B |
| Gross Profit | 55.34B | 55.39B | 58.61B | 61.35B | 63.94B |
| Gross Margin | 70.3% | 69.3% | 68.8% | 69.1% | 67.9% |
| Research & Development | 14.28B | 14.14B | 15.09B | 17.23B | 14.67B |
| Selling, General & Admin | 20.12B | 20.25B | 20.11B | 21.97B | 23.68B |
| Operating Expenses | 34.4B | 34.38B | 35.2B | 39.2B | 38.34B |
| Depreciation & Amortization | 7.39B | 6.97B | 7.49B | 7.34B | 7.5B |
| EBITDA | 26.75B | 26.61B | 23.32B | 24.78B | 41.06B |
| EBITDA Margin | 34.0% | 33.3% | 27.4% | 27.9% | 43.6% |
| Operating Income | 20.94B | 21.01B | 23.41B | 22.15B | 25.6B |
| Operating Margin | 26.6% | 26.3% | 27.5% | 24.9% | 27.2% |
| Interest Income | 53M | 490M | 1.26B | 1.33B | 1.06B |
| Interest Expense | 183M | 276M | 772M | 755M | 971M |
| Other Income / Expenses | (1.77B) | (1.65B) | (8.35B) | (5.46B) | 6.99B |
| Income Before Tax | 19.18B | 19.36B | 15.06B | 16.69B | 32.58B |
| Pre-Tax Margin | 24.4% | 24.2% | 17.7% | 18.8% | 34.6% |
| Income Tax Expense | 1.38B | 2.99B | 1.74B | 2.62B | 5.78B |
| Net Income | 20.88B | 17.94B | 35.15B | 14.07B | 26.8B |
| Net Margin | 26.5% | 22.4% | 41.3% | 15.8% | 28.5% |
| EPS (Basic) | 7.93 | 6.83 | 13.88 | 5.84 | 11.03 |
| EPS (Diluted) | 7.81 | 6.73 | 13.72 | 5.79 | 11.03 |
| Weighted Avg Shares | 2.63B | 2.61B | 2.53B | 2.41B | 2.43B |
| Weighted Avg Shares (Diluted) | 2.67B | 2.66B | 2.56B | 2.43B | 2.43B |
Johnson & Johnson
NYSE:JNJ
Intrinsic Alpha fair value
Locked
Current Price
$272.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.